Anna Mizutani
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Journal: British journal of cancer
Published: December 11, 2022
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.
Journal: Journal of medicinal chemistry
Published: March 24, 2020
Tankyrase promotes primary precursor miRNA processing to precursor miRNA.
Journal: Biochemical and biophysical research communications
Published: November 20, 2019
Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.
Journal: Oncogenesis
Published: September 13, 2019
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Journal: Journal of medicinal chemistry
Published: March 19, 2019
CNOT3 targets negative cell cycle regulators in non-small cell lung cancer development.
Journal: Oncogene
Published: June 14, 2018
ZEB1-regulated inflammatory phenotype in breast cancer cells.
Journal: Molecular oncology
Published: May 05, 2017
Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.
Journal: Oncogenesis
Published: April 09, 2017
APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.
APC Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal Cancer.
Journal: Molecular cancer therapeutics
Published: August 30, 2016
Last Updated: 09/26/2026